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Abstract
Background: Premature ovarian failure / primary ovarian insufficiency (POF/POI) associated with the mutations of
the FMR1 (Fragile-X Mental Retardation 1) gene belongs to the group of the so-called trinucleotide expansion
diseases. Our aim was to analyse the relationship between the paternally inherited premutation (PIP) and the maternally
inherited premutation (MIP) by the examination of the family members of women with POF, carrying the premutation
allele confirmed by molecular genetic testing.
Methods: Molecular genetic testing was performed in the patients of the 1st Department of Obstetrics and Gynecology
with suspected premature ovarian failure. First we performed the southern blot analyses and for the certified premutation
cases we used the Repeat Primed PCR.
Results: Due to POF/POI, a total of 125 patients underwent genetic testing. The FMR1 gene trinucleotide repeat number
was examined in the DNA samples of the patients, and in 15 cases (12%) deviations (CGG repeat number corresponding
to premutation or gray zone) were detected. In 6 cases out of the 15 cases the CGG repeat number fell within the range
of the so-called gray zone (41–54 CGG repeat) (4.8%, 6/125), and the FMR1 premutation (55–200 CGG repeat) ratio was 7.
2% (9/125). In 4 out of the 15 cases we found differences in both alleles, one was a premutation allele, and the other
allele showed a repeat number belonging to the gray zone. Out of 15 cases, only maternal inheritance (MIP) was
detected in 2 cases, in one case the premutation allele (91 CGG repeat number), while in the other case an allele
belonging to the gray zone (41 CGG repeat number) were inherited from their mothers. In 10 out of 15 cases, the
patient inherited the premutation allele only from the father (PIP). In 5 out of the 10 cases (50%) the premutation
allele was inherited from the father, and the repeat number ranged from 55 to 133. Out of 125 cases, 9 patients
had detectable cytogenetic abnormalities (7.2%).
Conclusions: The RP-PCR method can be used to define the smaller premutations and the exact CGG number.
Due to the quantitative nature of the RP-PCR, it is possible to detect the mosaicism as well.
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Background
The FMR1 gene mutation is an associated disease, belong-
ing to the so-called trinucleotid expansion diseases group.
These diseases, FRAXA (Fragile X syndrome), POF/POI
(premature ovarian failure) and FXTAS (tremor/ataxia
syndrome) are associated with a CGG repeats expansion,
which is located at the FMR1 gene promoter region.
There are two pathological FMR1 alleles: premutation
alleles have 55–200 repeats and full mutation alleles have
> 200 repeats [1].The premutation allele is associated with
the premature ovarian failure and the tremor/ataxia syn-
drome. The full mutation is responsible for the formation
of the X-linked dominant inherited fragile X syndrome
(Martin-Bell syndrome) [1].
The FMR1 gene encodes the protein FMRP, which is an
RNA binding protein and plays a significant role in the
transport processes of RNA, stabilization of RNA mole-
cules, and mRNA translation. The FMRP protein is
expressed in all tissues, but it was detected especially in
the brain, ovary and testis tissues in significant amounts.
Studies proved in fruit flies and mice, that due to the lack
of the FMRP protein some translational disturbances
occur, which affect the early neuronal development,
neurotransmission processes and synaptic connections.
The premutation and full mutation cases are not only
different in respect of the phenotype, but also the
expression of the FMRP protein. The hyper-expression
of the FMRP protein was confirmed in cases of premuta-
tion allele carriers, and the presence of the increased
level of the CGG repeat transcripts have a significant
role in the development of the phenotype.
In cases of the full mutation carrier FRAXA patients,
the high CGG repeat numbers are in association with
the heterochromatin condition, which results in the re-
duction/absence of the FMRP protein transcription.
Experiments have shown that in case of the premutation
allele, the transcription is characterised by active histone
modification, while the full mutation allele is charac-
terised by the hypermethylated condition, associated
with hypoacetylated histone proteins.
Mutations of the FMR1 gene play a role in the devel-
opment of three different conditions; the fragile X syn-
drome, premature ovarian failure and the tremor/ataxia
syndrome (FXTAS). Patients carrying the full mutation
allele are characterised by the fragile X syndrome. Chil-
dren with fragile X syndrome have a range of cognitive
impairments with boys typically more severely affected
than girls. The premutation involvement of the FMR1
gene was described in 3–15% of the premature ovarian
failure (POF), more recently known as primary ovarian
insufficiency (POI) cases. POF/POI disease is a condition
characterised by amenorrhoea, hypoestrogenism, ele-
vated gonadotropin levels and infertility occurring in
women before the age of 40 [2, 3].
Wheeler et al. also reported significantly higher rates
of hot flashes or flushes in premutation carriers (15.4%)
than controls (6.9%). CGG repeat size has been found to
be associated with the risk of earlier menopause but in a
non-linear manner, with the highest risk for those with
mid-range repeats (approximately 70 to 100) [4].
The risk of POF increases if the CGG repeat number
of the FMR1 gene exceeds 40, or if it falls in the
so-called gray zone (41–54) [1]. More recent population
studies have used 41–54 repeats. This discrepancy in the
definition of the gray zone has become more important
recently because several studies have now reported phe-
notypes associated with the gray zone or intermediate
allele sizes. In 2006, it was recognized that premature
ovarian insufficiency, which is associated with premuta-
tion expansions, is also present in gray zone expansion
carriers [4]. Population screening studies also suggested
that gray zone alleles are more highly represented in
ataxia phenotypes in general, including multiple system
atrophy, with rates as high as 8%. However, the preva-
lence rates are difficult to compare across studies given
the different study designs, with varying types of ataxia
patients included, mixed populations, differing ages, and
lack of collected controls [5]. The involvement of certain
gene defects in the POF disease shows wide variations,
with the involvement of the FMR1 gene being described
most frequently [1].
In carriers of the premutation allele the development
of the tremor/ataxia syndrome (FXTAS) was described.
The classic phenotype of the FXTAS is the kinetic
tremor and cerebellar ataxia, and other symptoms
include cognitive impairment, psychiatric disorders, per-
ipheral neuropathy and autonomic nervous system prob-
lems. The symptoms start at about 50 years of age. The
disease’s progression can show a great variety with a life
expectancy around 5 to 25 years following the appear-
ance of the symptoms [6]. 40–45% of the male premuta-
tion carriers and 8–16% of the female carriers showed
tremor/ataxia syndrome, wherein the first symptoms
were described at over 50 years of age. The background
of the pathogenicity of the other phenotype associated
with the premutation status, the tremor/ataxia syndrome
(FXTAS), is still not fully understood [7–9].
The possible links between the premutation status of
the POF/POI and tremor/ataxia syndrome FXTAS the
FMR1 gene were explained with two theories.
One theory is that the protein FMRP, which is an RNA
binding protein, encoded by the FMR1 gene, may be
expressed in larger quantities in the premutation car-
riers, and have a suppressor effect on the translation of
mRNAs encoded by a variety of other genes. Based on
these, it is also believed, that the reduced transcription
of the genes involved in the oocyte maturation might re-
sult in a reduced follicle stock [10, 11].
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According to the other theory, the accumulating mu-
tant FMR1 mRNA may have a long lasting toxic effect
on the ovary and this results in the premature destruc-
tion of the follicles.
The expression of the toxic RNA can be associated
with various clinical diseases, caused by both the pro-
teins bound to the RNA, and the influence of the alter-
native splicing mechanism of other genes.
The increased FMRP protein levels result in neuronal
toxicity, which can be detected in neurons and astro-
cytes as eosinophilic and ubiquitin positive nuclear
inclusions in the cerebrum, thalamus, basal ganglia, cra-
nial nerves and spinal cord [12, 13]. In the future the
additional neurological examinations of the relatives car-
rying the premutation status can give an opportunity to
detect any possible tremor/ataxia syndrome involve-
ment. In addition, the neurological examinations of the
premutation carrier female relatives could give an oppor-
tunity for the introduction of new test methods by map-
ping the differences with a potential diagnostic significance
[14, 15]. We assess the neurological status of the parents
by neurological examination and by using a special tremor
testing device. Our results will be reported later in another
publication.
The loss of AGG interruptions is thought to in-
crease the probability of transmission of a full muta-
tion allele. Yrigollen et al. studied the AGG
interruption and FMR1 CGG repeat allele stability
during transmission and concluded that the risk of
transmission by total length and AGG interruption
show that the odds of transmission to a full mutation
increase significantly with total length (P < 0.001). A
subject with 0 AGG interruptions and a total length
of 75 repeats would have an odds ratio 4.7 to 1 of
having a full mutation expansion and a subject with 0
AGG interruptions and 76 repeats would have an
odds ratio of 5.9 to 1 [16].
In European studies, in cases of POF/POI, the FMR1
premutation rate in the UK was 1.97% (5/254) and 10%
in Italy (19/190) [17, 18]. In South America, the FMR1
gene premutation rate in an Argentine population was
3.76% for POF/POI (5/133) [19]. From Asian countries,
the FMR1 premutation rates among POF/POI patients
were 0.53% (2/379) in China [20], 1.56% in Japan (2/128)
[21], and 2.14% (3/140) in India [22].
In the case of POF/POI, several researchers took into
consideration the intermediate cases classified in the
gray zone, in addition to the FMR1 premutation. Dean
et al. found the gray zone incidence rate 3.57% (5/140)
in an Indian population besides the FMR1 premutation
(2.14%, 3/140) in POI cases [22]. Bodega et al. demon-
strated 4.74% rate of gray zone cases (9/190) in Italian
POF/POI patients with 10% FMR1 premutation rate (19/
190) [18]. Guo et al. in China, with the occurrence of a
lower FMR1 premutation (0.53%, 2/379), demonstrated
2.9% (11/379) incidence rate of the gray zone cases [20].
The aim of the study was to explore the frequency of
expanded FMR1 alleles in women diagnosed with POF
and in their parents to determine parental origin. Our
aim was to analyse the relationship between the pater-
nally inherited premutation (PIP) and the maternally
inherited premutation (MIP) by the examination of the
family members of women with POF, carrying the pre-
mutation allele, which was confirmed by molecular gen-
etic testing.
Our study is the first genetic study in Hungary per-
formed on premature ovarian failure / primary ovarian
insufficiency (POF/POI) without previous population
based study.
Methods
The investigation process is the following: the patient
must be involved in genetic counselling and clinical data
should be included. If the patient suffers from POF dis-
ease, two blood samples are taken: one for the determin-
ation of hormone levels, and the other for molecular
genetic and cytogenetic analyses. Applying the G-banding
method we can determine the POF associated chromo-
some abnormalities. Our results on chromosome abnor-
malities will be reported in a publication later on.
The Southern blot analysis is suitable for determining
the FMR1 gene premutation and full mutation status,
and the RP-PCR can be used for the exact CGG repeat
number analyses. At the confirmed premutation cases
we also analyse the DNA sample of the parents if it is
possible.
Patients of the 1st Department of Obstetrics and
Gynaecology, Semmelweis University, with suspected
premature ovarian failure (POF) were included in the
study, after prior information and consent. The enrol-
ment criteria were the following: secondary amenor-
rhoea, the ovaries stopped functioning before 40 years of
age, FSH ≥ 40 IU/l in two different measurements and
low estrogen levels. Exclusion criteria were if a patient
had a surgery before, significantly affecting the follicle
stock in both ovaries, or medication was used, damaging
the ovarian function (chemotherapy).
Molecular genetic and cytogenetic (G-banding cyto-
genetic analyses) examinations were performed in cases
of women with suspected premature ovarian failure.
Southern blot analysis was performed during the mo-
lecular genetic analysis and the exact CGG repeat num-
ber was determined by the Repeat Primed polymerase
chain reaction (RP-PCR) method.
DNA was isolated from blood samples of the patients,
and the genomic DNA was digested with restriction
endonucleases EcoRI and EagI at 37 °C all night long.
Southern blot analysis was performed on the samples
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following the digestion, the samples were run on 0.5%
agarose gel for 18 h at 40 V voltage. As a result, the
DNA samples digested by restriction endonucleases,
were separated by size. After the separation, the sample
DNA was blotted from the agarose gel to the nitrocellu-
lose membrane by the capillary principle. The mem-
brane was probed with the radiolabeled Stb12.3 DNA
probe (FMR1 gene specific), using hybridisation at 65 °C
all night long. The principle of the method is random
priming technique [23, 24]. The unbound radioactive
probe was removed by incremental solutions (at 65 °C).
Using a Packard Instant Imager device we performed the
rapid measurement of the radioactive signals of the frag-
ments, their preliminary assessment; then we put a
Kodak XOMAT X-ray film on the membrane, and ex-
posed at − 100 °C for 4–5 days. At this rating the normal
fragment size in the healthy (normal) control group can
be measured at 2.8 kb, and about at 5.2 kb in accordance
with the inactive X. In the premutation cases the frag-
ment size was measured between 2.9–3.3 and 5.3–
5.7 kb.
The exact CGG repeat number was determined by the
Repeat Primed (RP)-PCR technique. The genomic DNA
sample was diluted to 20 ng/μl concentration, then we
used 2 μl for the LCD reaction. The PCR reaction was
performed with three primers, the FMR1 gene specific
primers (forward and reverse, FAM-labeled) and a
so-called CGG repeat primer together. The resulting
PCR products were separated by capillary electrophor-
esis according to size, and the amount of the product
can be determined based on the fluorescent signal inten-
sity. The method is also good for identifying the number
of AGG interruptions between CGG repeats.
Results
Due to premature ovarian failure, a total of 125 patients
underwent genetic testing. We examined the FMR1 gene
trinucleotide repeat number in DNA samples of the
patients, and in 15 cases (12%) we detected deviations
(CGG repeat number corresponding to premutation or
gray zone). In 6 cases out of the 15 cases the CGG
repeat number fell within the range of the so-called gray
zone (41–54 CGG repeat) (4.8%, 6/125), and the FMR1
premutation (55–200 CGG repeat) ratio was 7.2% (9/
125).
In 4 cases out of 15 cases we found differences in both
alleles, one was a premutation allele, and the other allele
showed a repeat number belonging to the gray zone.
(Table 1).
Out of 125 cases 9 patients had detectable cytogenetic
abnormalities (7.2%). No cases were found to have both
chromosome abnormalities and expanded FMR1 alleles.
About the findings of chromosome abnormalities we will
report in another publication.
At the confirmed premutation and gray zone cases we
completed the determination of the CGG repeat number
of the FMR1 gene of the family members, and studied
the maternal-paternal inheritance process.
Out of 15 cases, only maternal inheritance (MIP) was
detected in only 2 cases, in one case the premutation
allele (91 CGG repeat number), while in the other case
an allele belonging to the gray zone (41 CGG repeat
number) were inherited from the mother.
During the inheritance there was no expansion (CGG
repeat number increase) observed (Table 1).
In 10 cases out of 15 cases, the patient inherited the
premutation allele only from the father (PIP). In 5 out of
10 cases (50%), the premutation allele was inherited
from the father, and the repeat number ranged from 55
to 133. Expansion of the repeat number was observed in
4 of these cases during the inheritance process (75→ 79,
88→ 90, 70→ 74, 87→ 89 CGG repeat number expan-
sion). In three cases among the tested male relatives, the
neurodegenerative differences in the presence of premu-
tation or gray zone alleles were confirmed.
In 5 out of 10 cases (i.e. 50% of cases), the patient
inherited a paternal allele with a repeat number within
the gray zone. The repeat number varied between 41
and 46. Interestingly, in one case, the normal paternal
allele showed mosaic expansion (40 repeat number), the
patient had repeat numbers 22/42/52 in a mosaic form,
meaning that most likely a 40→ 42 and a 40→ 52 re-
peat number expansion occurred during the inheritance
of the paternal allele.
Figure 1. shows an example of the inheritance of the
paternal premutation allele. We confirmed 88 CGG pre-
mutation repeat in the paternal sample (367/1) (code of
the family/ code of the member of family), while the
mother (367/2) carried the normal 29, 30 CGG repeats.
Their daughter (367/4) inherited the normal 29 CGG
maternal and the premutation CGG 90 paternal alleles.
In this case the premutation paternal allele increased in
the offspring by 2 CGG repeats (88→ 90 CGG repeat
number expansion). (Fig. 1.)
Figure 2. shows an example of the inheritance of the
paternal allele within the gray zone.
In case of family No. 365 (Fig. 2), the father (365/1)
carried the 46 CGG repeat within the gray zone, the
mother (365/2) had the normal CGG 22 and 26 repeats,
and their daughter (365/5) carried the 26 and 46 CGG
repeats.
In 3 cases out of 15 cases maternal and paternal inher-
itance was simultaneously observed (PIP and MIP). In
each case, the inherited paternal allele was a premuta-
tion allele, while the patient inherited the maternal allele
with repeat numbers within the gray zone.
Interestingly, in one case we detected a mosaic form
in the father, with the 52/64/76 CGG repeat numbers
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using RP-PCR method. The patient inherited the pater-
nal allele with the 76 CGG repeat number, while the
inherited maternal allele was the 52 CGG repeat number
allele (Fig. 3).
In case of the mother (311/2) the 29 and 52 CGG
repeats were detected, the 52 CGG fell within the
gray zone. In the case of their daughter (311/4) we
confirmed the maternal allele with the 52 and the pa-
ternal allele with the 76 CGG repeats, and thus we
confirmed the premutation status as well. Her brother
inherited the normal maternal allele carrying the 29
CGG repeat (Fig. 3).
In 3 families, the expansion rate of the CGG repeat
number observed in the family exceeded 200, so full mu-
tation occurred. In one case, the patient’s son, in another
case his brother and in the third case other family mem-
bers were affected by fragile X syndrome (Table 1).
Figure 4. shows the RP-PCR results and the image of
the Southern blot. The father (436/4) carried the premu-
tation 87 CGG repeat, the patient (436/5) inherited the
paternal 87 CGG premutation allele, the 89 CGG repeat
number showed a low repeat number expansion. The
inherited maternal allele was a normal 29 CGG repeat
allele. We analysed the sample of the sister of the father,
and normal 30 CGG and premutation 87 CGG alleles
were confirmed. There were two cases of full mutation
form with the Fragile X syndrome in this family (Fig. 4.).
We investigated the presence of AGG interruptions
playing a role in the repeat number expansion. The
number of AGG interruptions was 3 in almost 50% of
the cases, CGG repeat number expansion occurred in
only one of these cases. If the number of AGG interrup-
tion was 0–2 (total of 8 cases), there were 4 cases of
CGG repeat number expansion of the examined pa-
tients, and if the patients and their family members were
taken into consideration together, the overall incidence
of CGG repeat expansion was 7.
Discussion
The primary aim of our research group was the clinical
and molecular genetic analysis of women involved in the
POF/POI disease, and the determination of the exact
CGG repeat numbers with the new RP-PCR method. In
the confirmed premutation cases we mapped the mater-
nal and paternal inheritance process by examining the
relatives.
In our material we detected 15 cases (12%) out of 125
cases, FMR1 premutation (9 cases) or gray zone (6 cases).
Table 1 In 6 cases the CGG repeat number was within the range 41–54 CGG repeat (gray zone), and in 9 cases we found FMR1
premutation (55–200 CGG repeat). In 4 cases we found differences in both alleles, one was a premutation allele, and the other allele
showed a repeat number belonging to the gray zone
Family
No
Code CGG repeat
number with
praemutation
caused
POF-POI
Allel number
with premutation
or gray zone
Premutation
(PM) or gray
zone (GZ)
Premutation
with paternal
(p) or maternal
(m) origin
Original
paternal
allel
Original
maternal
allel
Repeat
number
expansion
AGG
interruptions
(n)
Full
mutation
in family
Family
member
with full
mutation
1 191 30/91 1 PM m 30 91 no 2 91– > 200 son
2 252 41/55 2 PM and GZ p (PM) m (GZ) 55 41 no 0
3 258 22/79 1 PM p 75 22 75– > 79 1 75– > 200 brother
4 276 22/42/52
(mosaic)
1 GZ p 40 21 40– > 42/
40– > 52
3
5 296 50/82 2 PM and GZ p (PM) m (GZ) 82 49 no 0
6 311 52/76 2 PM and GZ p (PM) m (GZ) 52/64/
76
mosaic
52 no 3
7 310 29/58 1 PM p 58 29 no 3
8 327 29/42 1 GZ p 42 29 no 3
9 365 22/46 1 GZ p 46 23 no 3
10 367 29/90 1 PM p 88 30 88– > 90 2
11 377 23/45 1 GZ p 45 23 no 3
12 372 30/42 1 GZ p 42 29 no 2
13 375 23/41 1 GZ m 23 41 no 3
14 431 21/74 1 PM p 70 21 70– > 74 0
15 436 30/89 1 PM p 87 exit 87– > 89 2 87– > 200,
133– > 200
other
family
member
FMR1 gene CGG repeat numbers associated with POF/POI, allels with premutations and grey zones, and paternal/maternal origin
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Fig. 1 Paternal premutation allele inheritance (PIP) with low expansion (CGG repeat expansion 88 90). The figure shows the examination of the
family No.10 (code 367). The patient inherited the normal 29 CGG repeat number allele from the mother. The other allele was inherited from the
father, where the paternal 88 CGG repeat number expanded to 90 was observed in the patient. There was no evidence of AGG interruptions in
the father. The two AGG interruptions are in accordance with the maternal allele
Fig. 2 Inheritance of the paternal allele within the gray zone. The figure shows family No. 9 (code 365), the father (365/1) carries a 46 CGG repeat
within the gray zone, the mother (365/2) carries the normal 22 and 26 CGG, and their daughter (365/5) carries the 26 and 46 CGG repeats
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We performed an FMR1 RP-PCR study in POF/POI
patients for the first time in Hungary. If we examine
the FMR1 premutation ratio, the observed 7.2% (9/
125) in Europe is closer to the Italian results [18].
The ratio of the gray zone in POF/POI patients in
our own material was 4.8% (6/125), which corre-
sponded to the Italian results [18]. The ratio of the
FMR1 premutation and gray zone detected by us was
higher than in the Asian countries [20–22].
Based on our results, in the case of paternal inher-
itance, the FMR1 gene premutation CGG repeat
number is inherited to the next generation with
about the same number of repeats. In our studies we
did not detect any CGG repeats rising to full muta-
tion status in the offspring generation in paternal
inheritance cases. In the examined samples, we de-
tected premutation status in both the male and the
female offspring.
In the case of maternal inheritance, the full mutation
status is much more likely to occur in the offspring, de-
pending on the premutation CGG number; and the
number of the so-called AGG interruptions. The higher
the premutation repeat number of repeats and the lack
of AGG interruptions are, the more likely is that the full
mutation status occurs in the next generation. The dif-
ference between the paternal and maternal inheritance is
due to the difference between the male and female gam-
ete maturation.
The determination of the number of AGG interrup-
tions within the CGG repeat has a key role. If the
number of AGG interruptions is 1 or 0, we have to
consider the increase of the CGG repeat number oc-
curring in the offspring, which definitely increases the
risk of the FRAXA premutation or full mutation in
the case of a mother carrying a gray zone (41–54
CGG repeat number). So we can say that during fam-
ily planning the clinical geneticist should always con-
sider the exact CGG repeat number, and also the
number of AGG interruptions to give reliable results
for a personalized risk assessment. Using the RP-PCR
technique, these interruptions can be detected and
quantified, for which we could predict the risk of
CGG expansion possible in further generations.
Therefore, in the premutation cases with higher CGG
repeat numbers, the prenatal CGG repeat number
diagnosis is definitely justified in order to determine
the possible symptomatic fragile X syndrome.
Based on our experience, among the molecular genetic
test methods the Southern blot analysis is suitable to de-
tect the full mutation cases, higher premutation status,
and to isolate the methylated and unmethylated X
chromosome in the female specimens. The RP-PCR
method can be used to define the smaller premutations
and the exact CGG number. Due to the quantitative
nature of the RP-PCR, it is possible to detect the mosai-
cism as well.
Fig. 3 Paternal and maternal inheritance (PIP and MIP) with paternal mozaicism. The figure shows the family No.6 (code 311), where the maternal
and paternal inheritance was observed in parallel (PIP and MIP). The patient inherited the paternal premutation allele, and the maternal allele
with the repeat number within the gray zone. We detected mosaic form for the father with 52/64/76 CGG repeat numbers. The patient inherited
the paternal 76 CGG repeat number allele, and the maternal 52 CGG repeat number allele
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We found 15 cases of FMR1 gene premutations or
gray zone (12%), beside 9 chromosome abnormalities
(7.6%). Our findings are important and have significance
for the clinical care of these patients during genetic
counselling.
The limitation of the study is the few case numbers
which can’t give a reliable genotype-phenotype correl-
ation. Our study was the first genetic study in Hungary
performed on premature ovarian failure / primary ovar-
ian insufficiency (POF/POI) without other general popu-
lation based study.
Conclusions
The genetic examination of the premature ovarian fail-
ure is very important for the patient and her family also,
because the genetic results have serious influence on the
reproductive possibilities and family planning of the pre-
mutation carriers. The RP-PCR method can be used to
define the smaller premutations and the exact CGG
number. Due to the quantitative nature of the RP-PCR,
it is possible to detect the mosaicism as well.
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